

Michiel Adreanus van de Sande

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6777257/publications.pdf>

Version: 2024-02-01

152
papers

4,783
citations

101543
36
h-index

128289
60
g-index

160
all docs

160
docs citations

160
times ranked

3932
citing authors

#	ARTICLE	IF	CITATIONS
1	Soft tissue and visceral sarcomas: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 2021, 32, 1348-1365.	1.2	381
2	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet, The, 2019, 394, 478-487.	13.7	273
3	The Clinical Approach Toward Giant Cell Tumor of Bone. Oncologist, 2014, 19, 550-561.	3.7	199
4	Bone sarcomas: ESMOâ€“EURACANâ€“GENTURISâ€“ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2021, 32, 1520-1536.	1.2	150
5	Intercalary Allograft Reconstructions Following Resection of Primary Bone Tumors. Journal of Bone and Joint Surgery - Series A, 2014, 96, e26.	3.0	117
6	Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. Surgical Oncology, 2018, 27, 402-408.	1.6	116
7	Comparison between tripod and skin-fixed recording of scapular motion. Journal of Biomechanics, 2007, 40, 941-946.	2.1	113
8	Proximal humerus reconstruction after tumour resection: biological versus endoprosthetic reconstruction. International Orthopaedics, 2011, 35, 1375-1380.	1.9	94
9	LUMiCÂ® Endoprosthetic Reconstruction After Periacetabular Tumor Resection: Short-term Results. Clinical Orthopaedics and Related Research, 2017, 475, 686-695.	1.5	87
10	Higher incidence rates than previously known in tenosynovial giant cell tumors. Monthly Notices of the Royal Astronomical Society: Letters, 2017, 88, 688-694.	3.3	87
11	What Are the Long-term Results of MUTARSÂ® Modular Endoprostheses for Reconstruction of Tumor Resection of the Distal Femur and Proximal Tibia?. Clinical Orthopaedics and Related Research, 2017, 475, 708-718.	1.5	86
12	Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer, 2014, 120, 3159-3164.	4.1	83
13	Pathological muscle activation patterns in patients with massive rotator cuff tears, with and without subacromial anaesthetics. Manual Therapy, 2006, 11, 231-237.	1.6	77
14	Giant Cell Tumor With Pathologic Fracture: Should We Curette or Resect?. Clinical Orthopaedics and Related Research, 2013, 471, 820-829.	1.5	76
15	Treatment of pathological fractures of the long bones. EFORT Open Reviews, 2016, 1, 136-145.	4.1	76
16	Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncology, The, 2019, 20, 877-886.	10.7	75
17	Indications, complications, and results of shoulder arthroplasty. Scandinavian Journal of Rheumatology, 2006, 35, 426-434.	1.1	72
18	Conventional Primary Central Chondrosarcoma of the Pelvis. Journal of Bone and Joint Surgery - Series A, 2018, 100, 316-325.	3.0	72

#	ARTICLE	IF	CITATIONS
19	Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 264-276.	2.8	70
20	The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis). <i>Journal of Bone and Joint Surgery: British Volume</i> , 2012, 94-B, 882-888.	3.4	69
21	Fusion events lead to truncation of <i>FOS</i> in epithelioid hemangioma of bone. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 565-574.	2.8	69
22	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021, 6, 100170.	4.5	65
23	A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: Personalised sarcoma care (PERSARC). <i>European Journal of Cancer</i> , 2017, 83, 313-323.	2.8	63
24	Is there still a role for osteoarticular allograft reconstruction in musculoskeletal tumour surgery?. <i>Bone and Joint Journal</i> , 2017, 99-B, 522-530.	4.4	62
25	A multidisciplinary approach to giant cell tumors of tendon sheath and synovium—A critical appraisal of literature and treatment proposal. <i>Journal of Surgical Oncology</i> , 2013, 107, 433-445.	1.7	60
26	Long-term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study. <i>Developmental Medicine and Child Neurology</i> , 2017, 59, 1261-1268.	2.1	55
27	A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. <i>European Journal of Cancer</i> , 2020, 124, 77-87.	2.8	54
28	Liquid Nitrogen or Phenolization for Giant Cell Tumor of Bone?. <i>Journal of Bone and Joint Surgery - Series A</i> , 2014, 96, e35.	3.0	48
29	Quantitative Assessment of Fatty Degeneration in Rotator Cuff Muscles Determined With Computed Tomography. <i>Investigative Radiology</i> , 2005, 40, 313-319.	6.2	47
30	Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors. <i>JAMA Oncology</i> , 2022, 8, 345.	7.1	46
31	Mid-Term Outcome After Curettage with Polymethylmethacrylate for Giant Cell Tumor Around the Knee: Higher Risk of Radiographic Osteoarthritis?. <i>Journal of Bone and Joint Surgery - Series A</i> , 2013, 95, e159.	3.0	45
32	Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. <i>EClinicalMedicine</i> , 2019, 17, 100215.	7.1	42
33	Individualised risk assessment for local recurrence and distant metastases in a retrospective transatlantic cohort of 687 patients with high-grade soft tissue sarcomas of the extremities: a multistate model. <i>BMJ Open</i> , 2017, 7, e012930.	1.9	39
34	Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2018, 89, 570-574.	3.3	39
35	Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1226-1233.	0.8	39
36	Extrameningeal solitary fibrous tumors—surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet. <i>Cancer</i> , 2020, 126, 3002-3012.	4.1	39

#	ARTICLE	IF	CITATIONS
37	Teres major muscle activation relates to clinical outcome in tendon transfer surgery. Clinical Biomechanics, 2010, 25, 187-193.	1.2	38
38	MRI radiomics-based machine learning classification of atypical cartilaginous tumour and grade II chondrosarcoma of long bones. EBioMedicine, 2022, 75, 103757.	6.1	37
39	Perioperative Management of Extremity Soft Tissue Sarcomas. Journal of Clinical Oncology, 2018, 36, 118-124.	1.6	33
40	Dynamic prediction of overall survival for patients with high-grade extremity soft tissue sarcoma. Surgical Oncology, 2018, 27, 695-701.	1.6	33
41	Reliability of the classification of proximal femur fractures: Does clinical experience matter?. Injury, 2018, 49, 819-823.	1.7	32
42	High-grade soft tissue sarcomas of the extremities: surgical margins influence only local recurrence not overall survival. International Orthopaedics, 2015, 39, 935-941.	1.9	31
43	What Factors Are Associated With Implant Breakage and Revision After Intramedullary Nailing for Femoral Metastases?. Clinical Orthopaedics and Related Research, 2018, 476, 1823-1833.	1.5	31
44	Severity classification of Tenosynovial Giant Cell Tumours on MR imaging. Surgical Oncology, 2018, 27, 544-550.	1.6	31
45	Pathological Teres Major activation in patients with massive rotator cuff tears alters with pain relief and/or salvage surgery transfer. Clinical Biomechanics, 2006, 21, S27-S32.	1.2	30
46	Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints. Journal of Bone and Joint Surgery - Series A, 2019, 101, 1309-1318.	3.0	30
47	Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer, 2021, 127, 884-893.	4.1	29
48	Pigmented villonodular synovitis: a crowdsourcing study of two hundred and seventy two patients. International Orthopaedics, 2016, 40, 2459-2468.	1.9	28
49	Does $CSF1$ overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?. Histopathology, 2019, 74, 332-340.	2.9	28
50	Long-Term Clinical Outcomes of Intercalary Allograft Reconstruction for Lower-Extremity Bone Tumors. Journal of Bone and Joint Surgery - Series A, 2020, 102, 1042-1049.	3.0	28
51	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. Oncologist, 2021, 26, e863-e873.	3.7	28
52	The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life. Interactive Journal of Medical Research, 2018, 7, e4.	1.4	28
53	What Is the Role of Allogeneic Cortical Strut Grafts in the Treatment of Fibrous Dysplasia of the Proximal Femur?. Clinical Orthopaedics and Related Research, 2017, 475, 786-795.	1.5	26
54	The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. Orphanet Journal of Rare Diseases, 2021, 16, 191.	2.7	25

#	ARTICLE	IF	CITATIONS
55	Clinical implications of rotator cuff degeneration in the rheumatic shoulder. Arthritis and Rheumatism, 2008, 59, 317-324.	6.7	24
56	Determinants of impaired quality of life in patients with fibrous dysplasia. Orphanet Journal of Rare Diseases, 2017, 12, 80.	2.7	24
57	Prophylactic antibiotic regimens in tumour surgery (PARITY). Bone and Joint Research, 2015, 4, 154-162.	3.6	23
58	Radiologic differentiation of enchondromas, atypical cartilaginous tumors, and high-grade chondrosarcomasâ€”Improving tumor-specific treatment: A paradigm in transit?. Cancer, 2019, 125, 3288-3291.	4.1	23
59	Time dependent dynamics of wound complications after preoperative radiotherapy in Extremity Soft Tissue Sarcomas. European Journal of Surgical Oncology, 2019, 45, 684-690.	1.0	23
60	Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. Journal of Bone and Mineral Research, 2020, 36, 1729-1738.	2.8	23
61	Giant cell tumors of the sacrumâ€”a nationwide study on midterm results in 26 patients after intralesional excision. European Spine Journal, 2014, 23, 1949-1962.	2.2	22
62	Ext1 heterozygosity causes a modest effect on postprandial lipid clearance in humans. Journal of Lipid Research, 2015, 56, 665-673.	4.2	22
63	Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor. Future Oncology, 2020, 16, 2345-2356.	2.4	22
64	Unraveling the Heterogeneity of Sarcoma Survivorsâ€™ Health-Related Quality of Life Regarding Primary Sarcoma Location: Results from the SURVSARC Study. Cancers, 2020, 12, 3083.	3.7	22
65	Interobserver Variability in the Treatment of Little Finger Metacarpal Neck Fractures. Journal of Hand Surgery, 2014, 39, 1722-1727.	1.6	21
66	Prevalence and Clinical Features of Mazabraud Syndrome. Journal of Bone and Joint Surgery - Series A, 2019, 101, 160-168.	3.0	21
67	Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease. Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews, 2020, 4, e20.00028.	0.7	21
68	Current concepts in the treatment of giant cell tumour of bone. Current Opinion in Oncology, 2020, 32, 332-338.	2.4	21
69	Loss of Function in Heparan Sulfate Elongation Genes EXT1 and EXT 2 Results in Improved Nitric Oxide Bioavailability and Endothelial Function. Journal of the American Heart Association, 2014, 3, e001274.	3.7	20
70	Individualized approach to the surgical management of fibrous dysplasia of the proximal femur. Orphanet Journal of Rare Diseases, 2018, 13, 72.	2.7	20
71	Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study. Pediatric Blood and Cancer, 2020, 67, e28138.	1.5	20
72	Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging. Laboratory Investigation, 2020, 100, 1252-1261.	3.7	20

#	ARTICLE	IF	CITATIONS
73	Successful Pavlik treatment in late-diagnosed developmental dysplasia of the hip. International Orthopaedics, 2012, 36, 1661-1668.	1.9	19
74	Patient and diagnostic intervals of survivors of sarcoma: Results from the SURVSARC study. Cancer, 2020, 126, 5283-5292.	4.1	19
75	18F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma. Skeletal Radiology, 2019, 48, 1735-1746.	2.0	18
76	Bone sarcoma incidence in the Netherlands. Cancer Epidemiology, 2019, 60, 31-38.	1.9	18
77	Expandable distal femur megaprosthesis: A European Musculoskeletal Oncology Society study on 299 cases. Journal of Surgical Oncology, 2020, 122, 760-765.	1.7	17
78	Can we use MRI to detect clinically silent recurrent soft-tissue sarcoma?. European Radiology, 2020, 30, 4724-4733.	4.5	17
79	Surgical Technique: Tibia Cortical Strut Autograft Interposition Arthrodesis After Distal Radius Resection. Clinical Orthopaedics and Related Research, 2013, 471, 803-813.	1.5	16
80	Resuscitating extremities after soft tissue sarcoma resections: Are functional reconstructions an overlooked option in limb salvage? A systematic review. European Journal of Surgical Oncology, 2019, 45, 1762-1769.	1.0	16
81	External validation and adaptation of a dynamic prediction model for patients with high-grade extremity soft tissue sarcoma. Journal of Surgical Oncology, 2021, 123, 1050-1056.	1.7	16
82	Surgery for metachronous metastasis of soft tissue sarcoma – A magnitude of benefit analysis using propensity score methods. European Journal of Surgical Oncology, 2019, 45, 242-248.	1.0	15
83	The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function. Bone and Joint Journal, 2019, 101-B, 272-280.	4.4	15
84	Modular total shoulder system with short stem. A prospective clinical and radiological analysis. International Orthopaedics, 2004, 28, 115-118.	1.9	14
85	Neoadjuvant denosumab for extensive giant cell tumor in os ischium – a case report. Monthly Notices of the Royal Astronomical Society: Letters, 2015, 86, 393-395.	3.3	14
86	Outcome of acute staphylococcal prosthetic joint infection treated with debridement, implant retention and antimicrobial treatment with short duration of rifampicin. Journal of Infection, 2018, 76, 498-500.	3.3	14
87	Seeking international consensus on approaches to primary tumour treatment in Ewing sarcoma. Clinical Sarcoma Research, 2020, 10, 21.	2.3	14
88	Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review. Biomedicines, 2021, 9, 1388.	3.2	14
89	Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients. European Journal of Cancer, 2020, 141, 128-136.	2.8	13
90	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. Monthly Notices of the Royal Astronomical Society: Letters, 2021, 92, 493-499.	3.3	13

#	ARTICLE	IF	CITATIONS
91	Multiflora and Gram-Negative Microorganisms Predominate in Infections Affecting Pelvic Endoprostheses Following Tumor Resection. Journal of Bone and Joint Surgery - Series A, 2019, 101, 797-803.	3.0	12
92	Individualizing Follow-Up Strategies in High-Grade Soft Tissue Sarcoma with Flexible Parametric Competing Risk Regression Models. Cancers, 2020, 12, 47.	3.7	12
93	Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas. Journal of Bone and Joint Surgery - Series A, 2020, 102, 1703-1713.	3.0	12
94	Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center. Cancers, 2021, 13, 486.	3.7	12
95	The age-related impact of surviving sarcoma on health-related quality of life: data from the SURVSARC study. ESMO Open, 2021, 6, 100047.	4.5	12
96	Management of Soft Tissue Sarcomas in Extremities: Variation in Treatment Recommendations and Surveillance According to Specialty and Continent. Annals of Surgical Oncology, 2021, 28, 7923-7936.	1.5	12
97	Carriers of Loss-of-Function Mutations in EXT Display Impaired Pancreatic Beta-Cell Reserve Due to Smaller Pancreas Volume. PLoS ONE, 2014, 9, e115662.	2.5	12
98	Cross-Cultural Adaptation, Translation, and Validation of the Toronto Extremity Salvage Score for Extremity Bone and Soft Tissue Tumor Patients in Netherlands. Sarcoma, 2017, 2017, 1-6.	1.3	11
99	The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT. Surgical Oncology, 2020, 35, 261-267.	1.6	11
100	Can Orthopedic Oncologists Predict Functional Outcome in Patients with Sarcoma after Limb Salvage Surgery in the Lower Limb? A Nationwide Study. Sarcoma, 2014, 2014, 1-11.	1.3	10
101	Translation and adaptation of the Pediatric Outcome Data Collecting Instrument (PODCI) into the Dutch language and preliminary validation in children with Neonatal Brachial Plexus Palsy. Journal of Pediatric Rehabilitation Medicine, 2015, 8, 219-226.	0.5	10
102	Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases. Case Reports in Orthopedics, 2017, 2017, 1-6.	0.3	10
103	Tenosynovial Giant Cell Tumors in Children: A Similar Entity Compared With Adults. Clinical Orthopaedics and Related Research, 2018, 476, 1803-1812.	1.5	10
104	Screening program for neonates at risk for developmental dysplasia of the hip: comparing first radiographic evaluation at five months with the standard twelve-week ultrasound. A prospective cross-sectional cohort study. International Orthopaedics, 2019, 43, 1933-1938.	1.9	10
105	Time Trends and Prognostic Factors for Overall Survival in Myxoid Liposarcomas: A Population-Based Study. Sarcoma, 2020, 2020, 1-8.	1.3	10
106	Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review. Cancers, 2021, 13, 557.	3.7	10
107	Management of tenosynovial giant cell tumour of the foot and ankle. Bone and Joint Journal, 2021, 103-B, 788-794.	4.4	10
108	Regression of fibrous dysplasia in response to denosumab therapy: A report of two cases. Bone Reports, 2021, 14, 101058.	0.4	9

#	ARTICLE	IF	CITATIONS
109	Surgical management of 144 diffuse-type TGCT patients in a single institution: A 20-year cohort study. Journal of Surgical Oncology, 2022, 126, 1087-1095.	1.7	9
110	Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma. Endocrine, 2016, 54, 642-647.	2.3	8
111	Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma. Oncologist, 2020, 25, e716-e721.	3.7	8
112	Development and external validation of nomograms to predict sarcoma-specific death and disease progression after surgical resection of localized high-grade conventional primary central chondrosarcoma and dedifferentiated chondrosarcoma. Bone and Joint Journal, 2020, 102-B, 1752-1759.	4.4	8
113	Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors. Journal of Clinical Pharmacology, 2021, 61, 480-492.	2.0	8
114	The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC. European Journal of Cancer, 2022, 165, 71-80.	2.8	8
115	Trends in the surgical treatment of pathological fractures of the long bones. Bone and Joint Journal, 2018, 100-B, 1392-1398.	4.4	7
116	The Perceived Impact of Length of the Diagnostic Pathway Is Associated with Health-Related Quality of Life of Sarcoma Survivors: Results from the Dutch Nationwide SURVSARC Study. Cancers, 2020, 12, 2088.	3.7	7
117	Personalising sarcoma care using quantitative multimodality imaging for response assessment. Clinical Radiology, 2021, 76, 313.e1-313.e13.	1.1	7
118	Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort?. European Journal of Surgical Oncology, 2022, 48, 500-507.	1.0	7
119	Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1422-1432.	2.5	7
120	Incidence, treatment and outcome of abdominal metastases in extremity soft tissue sarcoma: Results from a multicentre study. Journal of Surgical Oncology, 2020, 121, 605-611.	1.7	7
121	Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches. Expert Opinion on Therapeutic Targets, 2022, 26, 333-345.	3.4	7
122	Range of motion implications of proximal humerus fractures: a case study. European Orthopaedics and Traumatology, 2011, 2, 153-156.	0.1	6
123	What Do We Know about Survival in Skeletally Premature Children Aged 0 to 10 Years with Ewing Sarcoma? A Multicenter 10-Year Follow-Up Study in 60 Patients. Cancers, 2022, 14, 1456.	3.7	6
124	Treatment Strategies for Metastatic Soft Tissue Sarcomas. Cancers, 2021, 13, 1722.	3.7	5
125	Therapy-Related Imaging Findings in Patients with Sarcoma. Seminars in Musculoskeletal Radiology, 2020, 24, 676-691.	0.7	5
126	The Association of Metastasis Pattern and Management of Metastatic Disease with Oncological Outcomes in Patients with Malignant Peripheral Nerve Sheath Tumors: A Multicenter Cohort Study. Cancers, 2021, 13, 5115.	3.7	5

#	ARTICLE	IF	CITATIONS
127	Infantile fibrosarcoma with an EGFR kinase domain duplication: Underlining a close relationship with congenital mesoblastic nephroma and highlighting a similar morphological spectrum. <i>Annals of Diagnostic Pathology</i> , 2022, 57, 151885.	1.3	5
128	Successful disinfection of femoral head bone graft using high hydrostatic pressure. <i>Cell and Tissue Banking</i> , 2018, 19, 333-340.	1.1	4
129	Comparison of the 7th and 8th version of the AJCC classification system for soft tissue sarcomas of extremities and trunk in patients with localised, intermediate or high-grade disease treated at European tertiary sarcoma centres. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2182-2188.	1.0	4
130	Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11042-11042.	1.6	4
131	Outcome of Surgical Treatment for Patients with Diffuse-Type Tenosynovial Giant Cell Tumours. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
132	The Influence of Personalised Sarcoma Care (PERSARC) Prediction Modelling on Clinical Decision Making in a Multidisciplinary Setting. <i>Sarcoma</i> , 2021, 2021, 1-6.	1.3	4
133	Biology and technology in the surgical treatment of malignant bone tumours in children and adolescents, with a special note on the very young. <i>Journal of Children's Orthopaedics</i> , 2021, 15, 322-330.	1.1	3
134	Intraosseous hibernoma of the appendicular skeleton. <i>Skeletal Radiology</i> , 2022, 51, 1325-1330.	2.0	3
135	Multimodality treatment of undifferentiated pleomorphic soft tissue sarcoma of the extremity (eUPS) in the elderly. <i>European Journal of Surgical Oncology</i> , 2022, 48, 985-993.	1.0	3
136	Prognostic Value of Quantitative [18F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma. <i>Diagnostics</i> , 2021, 11, 2271.	2.6	3
137	MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS11590-TPS11590.	1.6	3
138	Surgical challenges, novel techniques, and systemic treatment of giant cell tumour of bone of the distal radius. <i>Bone & Joint Open</i> , 2022, 3, 515-528.	2.6	3
139	Use of the Composite Pedicled Pectoralis Minor Flap after Resection of Soft Tissue Sarcoma in Reconstruction of the Glenohumeral Joint. <i>Case Reports in Orthopedics</i> , 2014, 2014, 1-5.	0.3	2
140	Clinical Outcome of Surgically Treated Leiomyosarcoma of the Extremities: A Retrospective Overview. <i>Anticancer Research</i> , 2020, 40, 5319-5325.	1.1	2
141	First prospective observational study in diffuse-type tenosynovial giant cell tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11560-11560.	1.6	2
142	Malignant Transformation of Giant Cell Tumor of Bone and the Association with Denosumab Treatment: A Radiology and Pathology Perspective. <i>Sarcoma</i> , 2022, 2022, 1-12.	1.3	2
143	Treatment of Prosthetic Joint Infection: Debridement, Antibiotics and Implant Retention With Short Duration of Rifampicin. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1
144	Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American) Tj ETQq0 0,0,rgBT /Oerlock 10	1.9	1

#	ARTICLE	IF	CITATIONS
145	The added value of chest imaging after neoadjuvant radiotherapy for soft tissue sarcoma of the extremities and trunk wall: A retrospective cohort study. European Journal of Surgical Oncology, 2022, , .	1.0	1
146	In Reply. Oncologist, 2014, 19, 1208-1208.	3.7	0
147	Assessing quality of life and experiences of diagnostic trajectories of sarcoma patients: The QUEST study protocol. Annals of Oncology, 2019, 30, v709.	1.2	0
148	Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort?. Journal of Clinical Oncology, 2021, 39, e23539-e23539.	1.6	0
149	Cartilage â€œ Forming Bone Tumours. , 2011, , 23-44.		0
150	Considering sarcoma staging systems and their implications to personalized care. Chinese Clinical Oncology, 2019, 8, S9-S9.	1.2	0
151	Patient and diagnostic intervals of sarcoma patients: Results from a survivorship study in the Netherlands.. Journal of Clinical Oncology, 2020, 38, e23553-e23553.	1.6	0
152	Patient journey and quality of life (QOL) among diffuse-type TGCT in the U.S.. Journal of Clinical Oncology, 2020, 38, e23565-e23565.	1.6	0